In vivo therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection

Gene Therapy

Volumn 18, Issue 10, 2011, Pages 945-952

  Ripoll, E ^a   Pluvinet, R ^b,c   Torras, J ^a   Olivar, R ^b   Vidal, A ^a   Franquesa, M ^a   Cassis, L ^a   Cruzado, J M ^a   Bestard, O ^a   Grinyo J M ^a   Aran, J M ^b   Herrero Fresneda, I ^a,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DURAN I REYNALS   (Spain)

^c Institute of Predictive and Personalized Medicine of Cancer   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

CD40 silencing; costimultation blockade; humoral rejection; renal transplant

Indexed keywords

APELIN; CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 7 RECEPTOR; MESSENGER RNA; RAPAMYCIN; SMALL INTERFERING RNA;

ACUTE VASCULAR REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; GENE SILENCING; GENE TARGETING; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY GRAFT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SEQUENCE ANALYSIS; SURVIVAL RATE;

ANIMALS; ANTIBODIES; ANTIGENS, CD40; DRUG THERAPY, COMBINATION; GENE SILENCING; GRAFT REJECTION; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; KIDNEY TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR; RNA, MESSENGER; RNA, SMALL INTERFERING; SIROLIMUS; STATISTICS, NONPARAMETRIC; TRANSPLANTATION, HOMOLOGOUS;

RATTUS;

EID: 80054055632     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.39     Document Type: Article

References (43)

1. Turgeon NA, Kirk AD, Iwakoshi NN. Differential effects of donor-specific alloantibody. Transplant Rev (Orlando) 2009; 23: 25-33.
2. Gilligan BJ, Woo HM, Kosieradzki M, Torrealba JR, Southard JH, Mangino MJ. Prolonged hypothermia causes primary nonfunction in preserved canine renal allografts due to humoral rejection. Am J Transplant 2004; 4: 1266-1273. (Pubitemid 39013572)
3. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17. (Pubitemid 30046812)
4. Shoker AS, Lun ZR, Choudry R, Saxena A. Analysis of the CD40/CD40L role in the sustenance of alloreactive antibody production. Transpl Immunol 2001; 8: 219-228. (Pubitemid 32249009)
5. Li XL, Menoret S, Le Mauff B, Angin M, Anegon I. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Transplantation 2008; 86: 10-15.
6. Rizvi M, Pathak D, Freedman JE, Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 2008; 14: 530-538.
7. Vowinkel T, Wood KC, Stokes KY, Russell J, Krieglstein CF, Granger DN. Differential expression and regulation of murine CD40 in regional vascular beds. Am J Physiol Heart Circ Physiol 2006; 290: H631-H639.
8. van Kooten C, Woltman AM, Daha MR. Immunological function of tubular epithelial cells: the functional implications of CD40 expression. Exp Nephrol 2000; 8: 203-207. (Pubitemid 30665889)
9. Yellin MJ, D'Agati V, Parkinson G, Han AS, Szema A, Baum D et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997; 40: 124-134. (Pubitemid 27044044)
10. Gaweco AS, Mitchell BL, Lucas BA, McClatchey KD, Van Thiel DH. CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection. Kidney Int 1999; 55: 1543-1552. (Pubitemid 29157155)
11. Mengel M, Mueller I, Behrend M, von Wasielewski R, Radermacher J, Schwarz A et al. Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection. Transpl Int 2004; 17: 293-300. (Pubitemid 39050196)
12. Pluvinet R, Olivar R, Krupinski J, Herrero-Fresneda I, Luque A, Torras J et al. CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling. Blood 2008; 112: 3624-3637.
13. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438. (Pubitemid 26162734)
14. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-8794. (Pubitemid 27335118)
15. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693. (Pubitemid 29289433)
16. Ossevoort MA, Ringers J, Kuhn EM, Boon L, Lorre K, van den Hout Y et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 1999; 68: 1010-1018. (Pubitemid 29489328)
17. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028. (Pubitemid 44343545)
18. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114. (Pubitemid 30082329)
19. Pluvinet R, Petriz J, Torras J, Herrero-Fresneda I, Cruzado JM, Grinyo JM et al. RNAimediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood 2004; 104: 3642-3646. (Pubitemid 39564440)
20. Herrero-Fresneda I, Franquesa M, Torras J, Vidal A, Aran J, Pluvinet R et al. Role of cold ischemia in acute rejection: characterization of a humoral-like acute rejection in experimental renal transplantation. Transplant Proc 2005; 37: 3712-3715. (Pubitemid 43015142)
21. Herrero-Fresneda I, Torras J, Vidal A, Lloberas N, Cruzado JM, Grinyo JM. Reduction of postischemic immune inflammatory response: an effective strategy for attenuating chronic allograft nephropathy. Transplantation 2005; 79: 165-173.
22. Sacks SH, Zhou W. Locally produced complement and its role in renal allograft rejection. Am J Transplant 2003; 3: 927-932. (Pubitemid 36917537)
23. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582-587. (Pubitemid 34633435)
24. Sacks S, Zhou W. New boundaries for complement in renal disease. J Am Soc Nephrol 2008; 19: 1865-1869.
25. Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion injury. Transplant Rev (Orlando) 2009; 23: 1-10.
26. Jang HR, Ko GJ, Wasowska BA, Rabb H. The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med 2009; 87: 859-864.
27. Burne-Taney MJ, Ascon DB, Daniels F, Racusen L, Baldwin W, Rabb H. B cell deficiency confers protection from renal ischemia reperfusion injury. J Immunol 2003; 171: 3210-3215. (Pubitemid 37093547)
28. Xu H, Yan J, Huang Y, Chilton PM, Ding C, Schanie CL et al. Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization. Blood 2008; 111: 3266-3275.
29. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004; 202: 250-265. (Pubitemid 39576917)
30. Andrade CF, Waddell TK, Keshavjee S, Liu M. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 2005; 5: 969-975. (Pubitemid 40571244)
31. Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005; 79: 505-514. (Pubitemid 40372243)
32. Weiler M, Kachko L, Chaimovitz C, Van Kooten C, Douvdevani A. CD40 ligation enhances IL-15 production by tubular epithelial cells. J Am Soc Nephrol 2001; 12: 80-87. (Pubitemid 32056792)
33. Kirkiles-Smith NC, Mahboubi K, Plescia J, McNiff JM, Karras J, Schechner JS et al. IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression. J Immunol 2004; 172: 1391-1396. (Pubitemid 38116780)
34. Lai PC, Smith J, Bhangal G, Chaudhry KA, Chaudhry AN, Keith Jr JC et al. Interleukin-reduces renal injury and glomerular NF-kappa B activity in murine experimental glomerulonephritis. Nephron Exp Nephrol 2005; 101: e146-e154.
35. Curti A, Ratta M, Corinti S, Girolomoni G, Ricci F, Tazzari P et al. Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood 2001; 97: 2758-2763.
36. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc 2008; 40: 3466-3469.
37. Kleinz MJ, Baxter GF. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept 2008; 146: 271-277.
38. Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 2004; 18: 1909-1911. (Pubitemid 39602280)
39. Han S, Wang G, Qi X, Englander EW, Greeley Jr GH. Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1068-G1078.
40. Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, Bosch J et al. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol 2009; 50: 296-305.
41. Kim SH, Zukowski K, Novak RF. Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells. Anticancer Res 2009; 29: 1143-1150.
42. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723. (Pubitemid 29082898)
43. Herrero-Fresneda I, Torras J, Cruzado JM, Condom E, Vidal A, Riera M et al. Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy? Am J Pathol 2003; 162: 127-137. (Pubitemid 36041995)